— ImmunoGen Inc. (NASDAQ: IMGN) reported its fourth-quarter 2019 earnings of $0.03 per share vs $0.05 per share loss expected. — Revenue jumped
Categories
pharma stocks
Regeneron Pharmaceuticals (REGN): Q4 2019 Earnings Snapshot
-- Regeneron Pharmaceuticals (NASDAQ: REGN) reported Q4 2019 earnings of $7.50 per share, vs. $6.92 expected. -- Revenues grew 13% to $2.17
Where does Merck (MRK) stand in the cancer-drug race?
Shares of Merck and Co. (NYSE: MRK) this week pared some of their recent gains even as the ex-dividend date approaches. While
Vertex Pharmaceuticals (VRTX): Q3 2019 Earnings Snapshot
-- Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected -- Total revenue grew
Amgen beats in Q3, raises guidance
Amgen Inc (NASDAQ: AMGN) reported third-quarter 2019 adjusted EPS of $3.66 on revenue of $5.74 billion. This was better than analysts’ prediction
AbbVie wins FDA approval for Rinvoq, stock gains
Shares of biopharmaceutical firm AbbVie (NYSE: ABBV) jumped 2.1% after the company received approval from the US Food and Drug Administration for
Intercept Pharmaceuticals beats in Q2, keeps full-year outlook unchanged
Intercept Pharmaceuticals (NASDAQ: ICPT) on Wednesday reported second-quarter results that surpassed Wall Street expectations, riding on the strong growth of its liver
Bausch Health stock rises on guidance hike
Bausch Health Companies Inc. (NYSE: BHC) said its revenues for the second quarter edged up 1% to $2.15 billion, in line with
Vericel reports Q2 earnings beat, raises outlook
Vericel Corporation (NASDAQ: VCEL) reported better-than-expected results in the second quarter aided by strong growth from both of its products. The company
Clovis Oncology dips further as loss widens in Q2
Clovis Oncology (NASDAQ: CLVS) on Thursday reported second-quarter results that were weaker than the street expectations. Total revenues rose 39% year-over-year to
Novartis reports better earnings on higher sales in Q2, raises guidance
Swiss pharmaceutical giant Novartis (NYSE: NVS) on Thursday surprised Wall Street by reporting a year-over-year increase in net earnings in Q2, helped
Q2 results will help investors merit Novartis’ strategic transformation
Novartis AG (NYSE: NVS) is scheduled to report second-quarter earnings before the opening bell on Thursday, July 18. The Switzerland-based pharmaceutical giant
AngioDynamics posts in-line EPS of $0.25 in Q4
AngioDynamics (NASDAQ: ANGO) posted fourth-quarter earnings results on Wednesday before the regular trading hours. Net sales for the period increased 9% to $96.3
Neptune Wellness posts wider losses in Q4, shares fall
Canadian producer of wellness products, Neptune Wellness Solutions (NASDAQ: NEPT), said its revenues fell 16% in the first quarter to $5.7 million,
Earnings preview: Advaxis stock treading near an all-time low ahead of Q2 results
Late-stage biotech firm Advaxis, Inc. (NASDAQ: ADXS) is scheduled to report second-quarter financial results on June 10, Monday, after the closing bell.
Solid Biosciences tumbles 38% to hit historic low
Shares of Solid Biosciences Inc. (NASDAQ: SLDB) opened 38% lower on Tuesday after the company said in its first-quarter results that its
InspireMD Q1 revenues plunge on third-party equipment failure
Israel-based medical device company InspireMD (NYSE: NSPR) reported a first-quarter loss of $3.82 per share, much wider than the loss of $2.50
Intercept Pharmaceuticals reports mixed Q1 results
Intercept Pharmaceuticals (NASDAQ: ICPT) reported wider-than-expected losses in the first quarter of 2019, primarily due to higher R&D expenses related to NASH
Earnings: Array BioPharma reports upbeat Q3 results
Array BioPharma (NASDAQ: ARRY) reported a narrower-than-expected loss in the third quarter of 2019, sending its shares up 0.5% during pre-market trading
Wall Street expects a revenue surge from GW Pharmaceuticals in Q1
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) is scheduled to report first-quarter 2019 earnings results on May 6, Monday, after the closing
ImmunoGen reports 57% decline in Q1 revenue
ImmunoGen Inc (NASDAQ: IMGN) on Friday reported weaker-than-expected top line in Q1, as the biotech firm continued to burn money on research